Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 5 min 33 sec ago

Exosome Diagnostics Completes $60 Million Series B Financing

Thu, 01/07/2016 - 14:28
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Exosome Diagnostics, Inc., the developer of a revolutionary liquid biopsy platform that enables non-invasive diagnosis of serious diseases, aiming to reduce or eliminate the need for tissue biopsies...
Diagnostics, Oncology, Venture Capital
Exosome Diagnostics, liquid biopsy

C4 Therapeutics Enters Strategic Drug Discovery Collaboration in the Promising New Field of Targeted Protein Degradation

Thu, 01/07/2016 - 14:22
BOSTON--(Healthcare Sales & Marketing Network)--C4 Therapeutics today announced that they will enter into a strategic collaboration with Roche to develop novel treatments in the field of targeted protein degradation (TPD) using C4’s Degronimid™ technology....
Biopharmaceuticals
C4 Therapeutics, Roche, Degronimid, targeted protein degradation

C4 Therapeutics Enters Strategic Drug Discovery Collaboration in the Promising New Field of Targeted Protein Degradation

Thu, 01/07/2016 - 14:22
BOSTON--(Healthcare Sales & Marketing Network)--C4 Therapeutics today announced that they will enter into a strategic collaboration with Roche to develop novel treatments in the field of targeted protein degradation (TPD) using C4’s Degronimid™ technology....
Biopharmaceuticals
C4 Therapeutics, Roche, Degronimid, targeted protein degradation

C4 Therapeutics Launches with $73 Million Series A Financing

Thu, 01/07/2016 - 14:15
Company to Translate Groundbreaking Degronimid™ Technology from Dana-Farber Cancer Institute into a New Class of Powerful Therapeutics Jason Fisherman, M.D. appointed Chief Executive Officer CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--C...
Biopharmaceuticals, Venture Capital, Personnel
C4 Therapeutics, Degronimid, targeted protein degradation

C4 Therapeutics Launches with $73 Million Series A Financing

Thu, 01/07/2016 - 14:15
Company to Translate Groundbreaking Degronimid™ Technology from Dana-Farber Cancer Institute into a New Class of Powerful Therapeutics Jason Fisherman, M.D. appointed Chief Executive Officer CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--C...
Biopharmaceuticals, Venture Capital, Personnel
C4 Therapeutics, Degronimid, targeted protein degradation

BioLight Reports Positive Second Clinical Study Results for its TeaRx(TM) Multi-Assay Test for Dry Eye Syndrome

Thu, 01/07/2016 - 14:01
TEL AVIV, Israel, January 7, 2016 -- (Healthcare Sales & Marketing Network) -- BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"), an emerging global ophthalmic company focused on t...
Diagnostics, Ophthalmology
BioLight Israeli Life Sciences Investments, TeaRx, dry eye syndrome

BioLight Reports Positive Second Clinical Study Results for its TeaRx(TM) Multi-Assay Test for Dry Eye Syndrome

Thu, 01/07/2016 - 14:01
TEL AVIV, Israel, January 7, 2016 -- (Healthcare Sales & Marketing Network) -- BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"), an emerging global ophthalmic company focused on t...
Diagnostics, Ophthalmology
BioLight Israeli Life Sciences Investments, TeaRx, dry eye syndrome

Alector Announces Closing of Series D Financing

Thu, 01/07/2016 - 13:51
Total Capital Raised in 2015 Exceeds $60M SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Alector LLC, a biotech company pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neu...
Biopharmaceuticals, Neurology, Venture Capital
Alector, neurodegenerative, immuno-modulatory

Alector Announces Closing of Series D Financing

Thu, 01/07/2016 - 13:51
Total Capital Raised in 2015 Exceeds $60M SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Alector LLC, a biotech company pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neu...
Biopharmaceuticals, Neurology, Venture Capital
Alector, neurodegenerative, immuno-modulatory

QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon

Thu, 01/07/2016 - 13:28
First-in-Human (FIH) Study evaluated feasibility, safety and performance of the Chocolate Heart Drug-Coated Coronary Balloon in de novo lesions Procedural outcomes demonstrated the incidence of bail-out stent placement, significant dissection, abrupt cl...
Devices, Interventional Cardiology
QT Vascular, Chocolate Heart, Drug-coated balloon, PTA

QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon

Thu, 01/07/2016 - 13:28
First-in-Human (FIH) Study evaluated feasibility, safety and performance of the Chocolate Heart Drug-Coated Coronary Balloon in de novo lesions Procedural outcomes demonstrated the incidence of bail-out stent placement, significant dissection, abrupt cl...
Devices, Interventional Cardiology
QT Vascular, Chocolate Heart, Drug-coated balloon, PTA

Intellijoint Surgical Receives FDA Clearance for the Next Generation of intellijoint HIP(TM) -- A Miniature Surgical Smart Tool for Cup Position, Leg Length, and Offset in Hip Replacement Surgery

Thu, 01/07/2016 - 13:03
WATERLOO, ON--(Healthcare Sales & Marketing Network) - Intellijoint Surgical Inc., a privately held Canadian medical technology company committed to developing and commercializing miniature surgical smart tools, announces today that it has been awarded US ...
Devices, Orthopaedic, FDA
Intellijoint Surgical, intellijioint HIP, hip replacement

Intellijoint Surgical Receives FDA Clearance for the Next Generation of intellijoint HIP(TM) -- A Miniature Surgical Smart Tool for Cup Position, Leg Length, and Offset in Hip Replacement Surgery

Thu, 01/07/2016 - 13:03
WATERLOO, ON--(Healthcare Sales & Marketing Network) - Intellijoint Surgical Inc., a privately held Canadian medical technology company committed to developing and commercializing miniature surgical smart tools, announces today that it has been awarded US ...
Devices, Orthopaedic, FDA
Intellijoint Surgical, intellijioint HIP, hip replacement

MST Receives FDA Clearance for "Follow Me(TM)" Image-Guided Software for Minimally Invasive Robotic Surgery

Wed, 01/06/2016 - 22:15
YOKNEAM, Israel, January 6, 2016 -- (Healthcare Sales & Marketing Network) --MST-Medical Surgery Technologies Ltd., a leader in the field of advanced image-based robotic technology, today announced that the U.S. Food and Drug Administration (FDA) has clea...
Devices, Surgery, FDA
Medical Surgery Technologies, AutoLap, Robotic Surgery, laparoscope

MST Receives FDA Clearance for "Follow Me(TM)" Image-Guided Software for Minimally Invasive Robotic Surgery

Wed, 01/06/2016 - 22:15
YOKNEAM, Israel, January 6, 2016 -- (Healthcare Sales & Marketing Network) --MST-Medical Surgery Technologies Ltd., a leader in the field of advanced image-based robotic technology, today announced that the U.S. Food and Drug Administration (FDA) has clea...
Devices, Surgery, FDA
Medical Surgery Technologies, AutoLap, Robotic Surgery, laparoscope

OvaScience Names Harald F. Stock Chief Executive Officer-Elect

Wed, 01/06/2016 - 15:39
Industry Veteran Brings Proven, Global Commercial Expertise Michelle Dipp Appointed Executive Chairman of the Board of Directors WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--OvaScienceSM (OVAS), a global fertility company focused on the di...
Devices, Personnel
OvaScience, EggPC, OvaTure, fertility treatment

Ivenix, Inc. Appoints MedTech Industry Veteran Stuart A. Randle as Chief Executive Officer

Wed, 01/06/2016 - 15:29
Follows Recent, Successful Closing of $42 Million Financing AMESBURY, Mass.--(Healthcare Sales & Marketing Network)--Ivenix, Inc., a medical technology company developing a next-generation infusion management platform, today announced the appointment of...
Devices, Personnel
Ivenix Inc, infusion pump

AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa

Wed, 01/06/2016 - 14:15
Hidradenitis suppurativa (HS) is a painful chronic inflammatory skin disease MONTREAL, Jan. 6, 2016 (Healthcare Sales & Marketing Network) - AbbVie, a global biopharmaceutical company, today announced that Health Canada approved HUMIRA® (adalimumab)...
Biopharmaceuticals, Regulatory
AbbVie, HUMIRA, adalimumab, hidradenitis

NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing

Wed, 01/06/2016 - 13:54
GERMANTOWN, Md. and NEW HAVEN, Conn., Jan. 6, 2016 -- (Healthcare Sales & Marketing Network) -- NextCure, Inc., a newly formed biopharmaceutical company focused on the discovery and development of new immuno-oncology products, today announced that it has ...
Biopharmaceuticals, Oncology, Venture Capital
NextCure, immunotherapy

Vascular Dynamics’ MobiusHD(TM) System Receives CE Mark for the Treatment of Resistant Hypertension

Wed, 01/06/2016 - 13:49
System offers novel approach for controlling hypertension using the body’s natural hypertension control mechanism MOUNTAIN VIEW, Calif.--(Healthcare Sales & Marketing Network)--Vascular Dynamics, Inc., a private medical device company developing novel s...
Devices, Cardiology, Regulatory
Vascular Dynamics, MobiusHD, resistant hypertension, hypertension

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong